Conference Coverage: ASCO 2023 – Focus on Breast Cancer
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making coming out of the ASCO 2023 conference.
FACULTY CHAIR
Adam Brufsky, MD, PhD, FACP
Magee-Womens Cancer Program at the UPMC Hillman Cancer Center, Pittsburgh, PA, USA
FACULTY MEMBERS
Joseph Gligorov, MD, PhD
AP-HP Tenon, Paris, France
Guy H. Jerusalem, MD, PhD
University of Liège/CHU de Liège, Belgium
Giuseppe Curigliano, MD, PhD
University of Milano, Italy
Nadia Harbeck, MD, PhD
Ludwig Maximilian University of Munich, Germany
Joyce O’Shaughnessy, MD
Baylor University Medical Center, Dallas, TX, USA
Peter A. Kaufman, MD
The University of Vermont Medical Center, Burlington, VT, USA
Mark Pegram, MD
Stanford University School of Medicine, Stanford, CA, USA
Sara Tolaney, MD, MPH
Dana-Farber Cancer Institute, Boston, MA, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Updates on Neoadjuvant Therapies for Breast Cancer
- CDK4/6 Inhibitors in the Treatment of HR+, HER2– Breast Cancer
- Novel Therapeutic Approaches for HR+, HER2– Breast Cancer
- Evolving Treatments for HER2+, HER2–, and HER2-Low Breast Cancer
